21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...
2270 Colonial Boulevard
Fort Myers, FL 33907
Founded in 1983
21St Century Oncology Holdings, Inc. Announces Executive Changes
Dec 2 14
On November 25, 2014, 21st Century Oncology Holdings, Inc. terminated its financial advisory and consulting agreement with FTI Consulting, Inc. Accordingly, pursuant to the terms of the agreement, effective as of December 26, 2014, David Beckman will no longer serve as the company’s Interim Chief Financial Officer. Joseph Biscardi, the Company’s Senior Vice President, Assistant Treasurer, Controller and Chief Accounting Officer, will continue to serve as the Company’s principal financial officer. The functions of Chief Financial Officer will be filled by individuals with significant tenure at the Company, including Richard Lewis, Chief Financial Officer-US Operations (9 years), Mr. Biscardi (17 years) and Frank G. English IV, Vice President-International Finance and Treasurer (3 years), until such time as a new Chief Financial Officer is appointed.
21st Century Oncology Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Announces Impairment Loss for the Third Quarter of 2014
Nov 13 14
21st Century Oncology Holdings, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s total revenues were $257,618,000 against $181,040,000 a year ago. Loss before income taxes was $85,475,000 against $23,363,000 a year ago. Net loss attributable to the company’s shareholder was $87,377,000 against $25,409,000 a year ago. Total pro-forma revenues $257,618,000 against $181,154,000 a year ago. Pro-forma Adjusted EBITDA was $40,057,000 against $23,214,000 a year ago. Total revenues were driven by the Company's acquisition activity and organic growth.
For the nine months, total revenues were $756,913,000 against $533,126,000 a year ago. Loss before income taxes was $316,279,000 against $59,075,000 a year ago. Net loss attributable to the company’s shareholder $325,082,000 against $65,289,000 a year ago. Net cash provided by operating activities was $11,690,000 against $2,562,000 a year ago. Net cash provided by operating activities was primarily driven by improved operational results, including contributions from the OnCure and SFRO transactions. Purchase of property and equipment was $44,269,000 against $25,109,000 a year ago. Total pro-forma revenues $765,732,000 against $568,414,000 a year ago. Pro-forma Adjusted EBITDA was $113,709,000 against $74,807,000 a year ago. The increase in total cash capital expenditures over last year reflects accelerated spending on the upgraded equipment and software at OnCure, which has already resulted in OnCure performing ahead of expectations. The company had $808 million of net debt at September 30, 2014.
For the third quarter of 2014, the company announced impairment loss of $47,526,000, primarily resulting from the finalization of the company's step 2 goodwill impairment analysis during the quarter.
21st Century Oncology Holdings, Inc. to Report Q3, 2014 Results on Nov 13, 2014
Nov 6 14
21st Century Oncology Holdings, Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Nov 13, 2014